Celgene Corp.

An analysis of $1B+ takeouts in 2016-24 finds biotechs opting for the billion dollar exit door in robust numbers

Plus: Lexicon, Pathios and Xeris name new CEOs, and updates from Jazz, AgomAb, VectorY, eTheRNA and more

Plus: Edward Dulac to become CFO at Intellia, and updates from Altimmune, Bayer, Compass, Sensorion and Neurona

Continuing diversity push under Viehbacher, Biogen obtains two programs spun out from MorphoSys, backed by Arch, Monograph, Jeito and others

Degrader-antibody conjugates double up on selectivity, but ‘DACs’ present optimization challenge

Approval marks the start of a new disease-modifying treatment paradigm for the rare disease and related indications

The clinical and commercial successes needed for Bristol Myers to navigate its upcoming patent cliff

Plus: new CSO at Nutcracker, and updates from 

Plus: Noema and K36 hire CMOs and more from Myricx, Outlook and IMIDomics

Gate Bio emerged from stealth with a $60M series A and a small molecule platform for selective gating of protein secretion